The FDA has approved fedratinib (Inrebic) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis.
Genomic profiling provides evidence of measurable residual disease in patients with acute myeloid leukemia and may help guide the choice of a preconditioning regimen in those who are at risk of relapse after undergoing allogeneic hematopoietic cell transplantation.
Jorge Cortes, MD, discusses frontline advances, discontinuation, and remaining challenges in the chronic myeloid leukemia paradigm.
With the recent publication of an inaugural set of guidelines for treatment of pediatric acute lymphoblastic leukemia, the National Comprehensive Cancer Network seeks to introduce standards to a branch of care long dominated by clinical trial protocols.
Elias Jabbour, MD, highlights the evolving armamentarium and next steps in the treatment paradigm for acute myeloid leukemia.
The FDA has approved PF-05280586, a biosimilar for rituximab, for the treatment of adult patients with CD20-positive B-cell non-Hodgkin lymphoma as a single agent or in combination with chemotherapy, or for patients with CD20-positive chronic lymphocytic leukemia in combination with chemotherapy.
Gary J. Schiller, MD, discusses the challenges with treating patients with hairy cell leukemia and some emerging therapies that could impact clinical practice.
After decades of quiescence, the therapeutic landscape of hairy cell leukemia is undergoing rapid evolution.
Jing-Zhou Hou, MD, PhD, highlights the research being conducted in the realm of lymphoma, including positive and negative trials that have read out in the space, and provides insight into novel approaches under investigation.
Ariela Noy, MD, discusses a phase II trial of devimistat in Burkitt lymphoma and other lymphomas, and describes the unique mechanism of action of the agent.